LLY241213P800000
- 9.05
- -9.17-50.33%
Eli Lilly and Co Newsroom
Eli Lilly and Co's blockbuster new drug "Tirzepatide" has filed its fifth marketing application in China.
On December 14, the latest announcement on the CDE website states that Eli Lilly and Co (LLY.US) has had its new indication application for the blockbuster drug GIP/GLP-1 receptor dual agonist tirzepatide injection accepted.
INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) have reached a commercialization agreement for "Jepalin" in mainland China.
INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) announced a collaboration agreement regarding the rights of Eli Lilly’s non-covalent (reversible) BTK inhibitor "Jehpaili" (100 mg and 50 mg tablets) in mainland China. INNOVENT BIO will be responsible for the import, sale, promotion, and distribution of Jehpaili, while Eli Lilly will be responsible for the research and development and post-marketing medical affairs related work for Jehpaili. INNOVENT BIO's founder, Chairman and CEO Yu Dechao expressed great pleasure in further deepening the strategic cooperation with Eli Lilly, noting that Jehpaili is the latest generation, the first and only globally approved non-covalent (reversible) BTK inhibitor.
INNOVENT BIO (01801) has reached a commercialization cooperation with Eli Lilly and Co regarding a new cancer drug based on BTK inhibitors.
On December 16, INNOVENT BIO (01801) and Eli Lilly and Co jointly announced the following cooperation agreement regarding Eli Lilly's non-covalent (reversible) BTK inhibitor, Jaypalta (100 mg and 50 mg tablets), in mainland China: INNOVENT BIO will be responsible for the import, sales, promotion, and distribution of Jaypalta; Eli Lilly will be responsible for the research and development as well as post-marketing medical affairs related work.
Express News | Innovent Biologics Inc - Lilly to Manage R&D and Post-Market Medical Affairs for Jaypirca
INNOVENT BIO and Eli Lilly and Co are deepening their collaboration in the field of oncology, having reached a commercialization agreement for Epaned (Pibrentasvir tablets) in mainland China.
San Francisco, USA and Suzhou, China, December 16, 2024 /PR Newswire/ -- INNOVENT BIO (Hong Kong Stock Exchange Code: 01801) (hereinafter referred to as "INNOVENT BIO"), a biopharmaceutical company committed to the research, development, production, and sales of innovative drugs for major diseases such as oncology, autoimmune, metabolic and cardiovascular, and ophthalmology, today announced a collaboration with Eli Lilly and Co (New York Stock Exchange Code: LLY) regarding the rights to Eli Lilly's non-covalent (reversible) BTK inhibitor, Jibali (100 mg and 50 mg tablets) in mainland China.
Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (Pirtobrutinib) in Mainland China
Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50
Why Is Eli Lilly and Company (LLY) Among the Best Income Stocks to Buy According to Analysts?
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Eli Lilly's Mounjaro Won't Have Separate Indication for Obstructive Sleep Apnea, European Regulator Says
EMA: Eli Lilly and Co (LLY.US) weight loss drug Mounjaro can also treat sleep apnea without the need for additional indications.
An expert group from the European Union's pharmaceutical regulatory agency EMA has determined that Eli Lilly and Co's weight loss drug Mounjaro does not require a separate indication for the treatment of obstructive sleep apnea (OSA).
US Stock Outlook | Is the unemployment rate in the USA showing warning signs? Societe Generale warns: there will be a risk of recession next year; AI chip stocks are soaring in pre-market, Broadcom has risen over 17% after earnings.
Meta has released a new AI model that will enhance the Metaverse experience; with multiple Bullish factors combined, Taiwan Semiconductor rose over 2% in pre-market trading; Eli Lilly and Co's Mounjaro has replaced Novo-Nordisk A/S's Wegovy, becoming the new favorite weight loss drug in the United Kingdom.
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Eli Lilly Gets Key European Backing for Omvoh in Crohn's Disease
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Express News | Eli Lilly and Co - European Commission Decision on Omvoh Expected in Next 1-2 Months
Express News | Eli Lilly and Co - Expects U.S. Decision on Omvoh for Crohn's Disease in H1 2025
Express News | Lilly's Omvoh® (Mirikizumab) Recommended by Chmp for Approval in the European Union for Adults With Moderately to Severely Active Crohn's Disease
Express News | EMA's Chmp: Finalised Assessment of Application to Extend Use of Mounjaro to Include Treatment of Obstructive Sleep Apnoea in Adults With Obesity
Eli Lilly and Co (LLY.US) Mounjaro has replaced Novo-Nordisk A/S (NVO.US) Wegovy as the new favorite weight loss drug in the United Kingdom.
The number of private individuals in the United Kingdom purchasing weight loss drugs is continuously increasing, with Eli Lilly and Co's Mounjaro gradually surpassing Novo-Nordisk A/S's Wegovy, becoming a new favorite among consumers.